Compare Fidelity National Information Servcs Inc (FIS) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Heron Therapeutics Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Fidelity National Information Servcs Inc is far larger — about 260.4× Heron Therapeutics Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Heron Therapeutics Inc for 35 Days on average.
| FIS | HRTX | |
|---|---|---|
Market Cap | $17.71B | $68.01M |
Volume | 9,047,825 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $67.94 | $1.49 |
52-Week Low | $32.44 | $0.27 |
Typical Hold Time | 88 Days | 35 Days |
Enterprise Value | $38.22B | $174.75M |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth from $10.68B in 2025 to projected $12.2B in 2026 and net income margin expanding to 27.65%. Recent business wins include core banking platform selections and embedded banking launches, positioning FIS for modernization growth. Analyst consensus remains strongly bullish with a $47.15 price target representing 37% upside potential.
FIS presents a compelling value opportunity with attractive valuation multiples (P/E 5.27, P/S 1.46) and strong analyst support, though investors face risks from negative cash flow trends, high debt levels, and technical bearish signals. The company's strategic positioning in banking technology modernization provides growth catalysts, but execution risks and market volatility require careful monitoring.
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
